B超引导下选择性门静脉化疗栓塞在肝癌治疗中的应用

Combined Superselective TACE with Selective Portal Vein Chemoembolization for the Treatment of Unresectable Advanced PHC

目的:探讨超选择肝动脉化疗栓塞(TACE)联合经皮穿刺导管选择性门静脉化疗栓塞(SPVCE)治疗中晚期原发性肝癌(PHC)的价值。方法:将133例中晚期PHC随机分成2组,对照单纯的选择性肝动脉化疗栓塞(TACE)与TACE加SPVCE的治疗效果。结果:TACE组和TACE加SPVCE总有效率[缓解和部分缓解(CR+PR)]分别为38%和59%,差异有显著意义(p<0.01),0.5、1、2年生存率TACE组分别为93.1%、65.4%、36.1%,TACE加SPVCE组分别为100%、95.1%、59.8%。两组差异有显著意义(p<0.01)。结论:TACE加SPVCE治疗中晚期PHC是一种有效的方法,效果优于单纯的TACE。

Objective: To evaluate superselective transcatheter arteial chemoembolization(TACE) plus selective portal vein chemoembolization(SPVCE) on unresectable advanced primary hepatocellular carcinoma (PHC).Method: 133 cases of advanced PHC were randomly divided into group treated with ordinary TACE, and that with TACE+SPVCE.Result:The rate(CR+PR) was 38% in TACE group and 59% in TACE+SPVCE group(P<0.01). The 0.5、1、2 years survival rate was 93.1%、65.4% and 36.6% in TACE group and 100%、95.1% and 59.8%in TACE+SPVCE group(p<0.01) respectively.Conclusion: TACE+SPVCE or the treatment of PHC is superior to TACE alone.